Thestocktraderhubzee Posted - 04/19/24

WATCHLIST APR 19 2024 $BPTH Roth MKM Reiterates Buy on Bio-Path Hldgs, Maintains $40 Price Target $USB DA Davidson Maintains Neutral on U.S. Bancorp, Lowers Price Target to $44 $VIGL JMP Securities Reiterates Market Outperform on Vigil Neuroscience, Maintains $23 Price Target $SPGI Stifel Maintains Buy on S&P Global, Lowers Price Target to $442 $SMTC Stifel Maintains Buy on Semtech, Raises Price Target to $36

DonCorleone77 Posted - 04/17/24

$VIGL Vigil says interim IGNITE Phase 2 data demonstrate VGL101 potential for ALSP Vigil Neuroscience announced the presentation of multiple oral and poster presentations on the company's lead clinical candidate iluzanebart at the 2024 American Academy of Neurology AAN Annual Meeting. "We are excited to see our enthusiasm for iluzanebart matched by clinical leaders in the ALSP community. The interim findings from both the IGNITE Phase 2 and ILLUMINATE Natural History studies support the potential of iluzanebart to become the first, disease-modifying therapy for those living with ALSP," said Petra Kaufmann, M.D., F.A.A.N, Chief Medical Officer of Vigil. "Both trials have led to an incredible step forward - not only in understanding ALSP disease progression, but also in drawing parallels between biomarkers and correlating clinical outcomes. "Vigil's interim IGNITE data demonstrated that iluzanebart was well-tolerated, and the data suggest a favorable impact on the protein product of the CSF1R gene whose dysfunction is the causal driver of ALSP," said Zbigniew Wszolek, M.D., consultant in the Department of Neurology at the Mayo Clinic. "Positive trends on MRI measurements support slowing in irreversible neurodegeneration, and to see these signals in patients as early as six months is very encouraging."..."The findings from ILLUMINATE highlight sensitive markers of ALSP pathophysiology that have the potential to provide valuable insight into clinical endpoints and improve the overall understanding of ALSP disease progression to inform future study designs," said David Lynch, Ph.D., Honorary Research Fellow, Department of Neuromuscular Diseases, University College London.

Stock_Titan Posted - 04/17/24

$VIGL Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting https://www.stocktitan.net/news/VIGL/vigil-presents-key-findings-from-illuminate-ignite-studies-in-alsp-ki32x35r0xlm.html

Tshanky_ Posted - 04/11/24

$VIGL needs volume, but like the opportunity

Tshanky_ Posted - 04/09/24

$VIGL 👀

frontiere Posted - 04/06/24

$VIGL any reasons why Vigil is NOT a Buy at the current $3.33 price per share? 🤔

G101SPM Posted - 03/28/24

@S_Franconi per request: $VIGL $3.20 carries SPM 79.14 tag as neutral suggests company doesn't have enough cash to complete trials for VGL101 (Iluzanebart) without major dilution. If a joint venture can be established, the tag increases to SPM 87.41 with EXIT at $25.00.

S_Franconi Posted - 03/28/24

$VIGL 143 Watchers as of 3/28/24.

S_Franconi Posted - 03/28/24

$VIGL April 14th - VGL101 - (ILLUMINATE) 2024 American Academy of Neurology (AAN) Annual Meeting.

S_Franconi Posted - 03/28/24

$VIGL VGL101 - (IGNITE) 2024 American Academy of Neurology (AAN) Annual Meeting on April 17, 2024.

S_Franconi Posted - 03/28/24

@G101SPM Can you run $VIGL?

RamenLives Posted - 03/27/24

$VIGL

DonCorleone77 Posted - 03/26/24

$VIGL Vigil Neuroscience sees cash runway into 2H25 Cash, cash equivalents, and marketable securities were $117.9 million as of December 31, 2023, compared to $133.6 million as of September 30, 2023. In January 2024, the Company announced that it extended its projected cash runway into the second half of 2025.

DonCorleone77 Posted - 03/26/24

$VIGL Vigil Neuroscience reports Q4 EPS (57c), consensus (53c) "Among our many recent milestones, the most significant for Vigil was the positive data readout from our ongoing Phase 2 IGNITE trial and ILLUMINATE Natural History Study. Findings from these studies have provided critical insights and a rich dataset on biomarkers that we believe support our strategy to advance iluzanebart through clinical development as quickly as possible. We are also pleased to have enrolled 20 patients in our IGNITE trial, exceeding our target of 15 patients. This is a true testament to the importance of our mission to bring a novel therapy to ALSP patients," said Ivana Magovevi-Liebisch, Ph.D., J.D., President and Chief Executive Officer of Vigil. "Our Phase 1 clinical trial evaluating VG-3927 in healthy volunteers is progressing as planned and we are on track to provide an interim data readout in mid-2024. As the first and only clinical-stage small molecule TREM2 agonist..."

Stock_Titan Posted - 03/26/24

$VIGL Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update https://www.stocktitan.net/news/VIGL/vigil-neuroscience-reports-fourth-quarter-and-full-year-2023-v9onka42galq.html

Ti5 Posted - 03/18/24

$VIGL mucho

S_Franconi Posted - 03/16/24

$VIGL @G101SPM Can you run this?

Ti5 Posted - 03/15/24

$VIGL tutes loading up for sure. Market down, but we up

Stock_Titan Posted - 03/13/24

$VIGL Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting https://www.stocktitan.net/news/VIGL/vigil-announces-upcoming-presentations-at-2024-american-academy-of-2wmsziugno2r.html

Stock_Titan Posted - 03/12/24

$VIGL Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days https://www.stocktitan.net/news/VIGL/vigil-neuroscience-to-present-at-stifel-2024-virtual-cns-fnymw26uz8vj.html

Stock_Titan Posted - 03/06/24

$VIGL Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024 https://www.stocktitan.net/news/VIGL/vigil-announces-oral-presentation-on-small-molecule-trem2-agonist-vg-0j4jwi8ch0jo.html

Stock_Titan Posted - 02/29/24

$VIGL Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024 https://www.stocktitan.net/news/VIGL/vigil-presents-poster-on-impacts-of-misdiagnosis-and-genetic-testing-ymp5kev18m3a.html

Bugseason Posted - 02/23/24

$VIGL haulted for great news.

Bugseason Posted - 02/18/24

$VIGL I like the ceo and management. im in for the long haul. Science is interesting.

Ti5 Posted - 02/12/24

$VIGL something must be cooking

Bugseason Posted - 02/09/24

$VIGL conference had to be good

Stock_Titan Posted - 02/07/24

$VIGL Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference https://www.stocktitan.net/news/VIGL/vigil-neuroscience-to-present-at-guggenheim-6th-annual-biotechnology-yvy4apnly4i9.html

Bugseason Posted - 01/31/24

$VIGL buy and hold $10 by the fall . mid year results

frontiere Posted - 01/20/24

$BNOX a + sign for me is that Spyros and his team was v likely poached / convinced to join from $VIGL , not fired / other negative. Resigned 11 Dec’22 effective 4 Jan’23. Signed w BNOX 16 Dec’22 effective 5 Jan’23. Base salary up 25% from 400k to $500k+, plus 50% bonus, plus 27m stock options (Aus? So ≈150k ADS??) struck at effective $3+ ADS (5day trailing pre 21 Feb’23…very approx). Can Spyros achieve what Jan Skvarka did with $TRIL Trillium? 🤔😁 Dream, dream, dream.

StockAutomatePro Posted - 01/17/24

$VIGL Not a good sign on the charts stock is headed downwards. We alerted the SELL signal at $3.45 and we were able to close this one with profit at $2.98 🥳